Menon Venu, Rumsfeld John S, Roe Matthew T, Cohen Mauricio G, Peterson Eric D, Brindis Ralph G, Chen Anita Y, Pollack Charles V, Smith Sidney C, Gibler W Brian, Ohman E Magnus
Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Am J Med. 2006 Jul;119(7):584-90. doi: 10.1016/j.amjmed.2006.01.018.
An analysis of reginal variation across the United States in the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) has not been previously performed.
We assessed contemporary practice and outcomes in 56,466 high-risk patients with NSTE ACS (positive cardiac markers and/or ischemic ST-segment changes) admitted to 310 hospitals across four defined regions in the United States from January 1, 2001, to September 30, 2003. Patient clinical characteristics, acute (<24 hours) and discharge medications, in-hospital procedures, and in-hospital case-fatality rates were evaluated.
Statistically significant but clinically small differences in baseline characteristics including age, gender, rates of diabetes, hypertension, and smoking, as well as medical treatment, including a greater than 5% variation in acute use of beta-blockers, clopidogrel, and statins use, were noted across regions. Adjusted rates of revascularization were similar across regions. Overall in-hospital case-fatality rate was 4.1%, with the highest rates in the Midwest (4.6%) and the lowest in the Northeast (3.5%). Adjusted odds ratios (OR) (95% confidence interval [CI] for death were significantly higher in the Midwest (OR 1.42, CI 1.19-1.70), West (OR 1.40 CI 1.05-1.87), and South (OR 1.33, CI 1.08-1.62), compared with the Northeast.
Management of high-risk patients with NSTE ACS is relatively uniform across the United States. However, in-hospital case-fatality rates vary significantly by region, and the differences are not explained by adjustment for standard clinical variables.
此前尚未对美国各地非ST段抬高型急性冠状动脉综合征(NSTE ACS)患者的治疗及预后的区域差异进行分析。
我们评估了2001年1月1日至2003年9月30日期间,美国四个特定区域的310家医院收治的56466例高危NSTE ACS患者(心肌标志物阳性和/或缺血性ST段改变)的当代治疗情况及预后。评估了患者的临床特征、急性(<24小时)及出院时用药、住院期间的操作以及住院病死率。
各区域在包括年龄、性别、糖尿病、高血压及吸烟率等基线特征方面存在统计学显著但临床差异较小,在药物治疗方面,β受体阻滞剂、氯吡格雷及他汀类药物的急性使用率差异超过5%。各区域血管重建的校正率相似。总体住院病死率为4.1%,中西部地区最高(4.6%),东北地区最低(3.5%)。与东北地区相比,中西部地区(比值比[OR] 1.42,95%置信区间[CI] 1.19 - 1.70)、西部地区(OR 1.40,CI 1.05 - 1.87)及南部地区(OR 1.33,CI 1.08 - 1.62)的校正死亡比值比(OR)(95% CI)显著更高。
美国各地对高危NSTE ACS患者的管理相对统一。然而,住院病死率因区域而异,且这些差异无法通过对标准临床变量进行校正来解释。